About Us
The core of ZuriMED is built by its people.
Our interdisciplinary and diverse team is backed by a strong board of directors comprised of world renowned experts. Together, we aim to push the boundaries of current orthopedic and sports medicine solutions through our innovative technologies.
About Us
The core of ZuriMED is built by its people.
Our interdisciplinary and diverse team is backed by a strong board of directors comprised of world renowned experts. Together, we aim to push the boundaries of current orthopedic and sports medicine solutions through our innovative technologies.

ZuriMED originated in Zurich, Switzerland, and is part of the Swiss health cluster. Surrounded by world-leading universities and orthopedic healthcare institutes, we have unique access to high-quality labs, clinical knowledge, and exceptionally skilled talents.
The startup spun off from the University of Zurich and ETH Zurich and is supported by Balgrist Beteiligungs AG, currently located at Balgrist Campus. With this, we benefit from close collaborations with research groups and clinicians, accelerating the transition from bench to bedside.

Our Values
Innovation
We embrace creativity and entrepreneurial thinking, developing groundbreaking technologies to pioneer advancements and reshape the future of healthcare.
Ambition
Our relentless pursuit of excellence and our vision of improving patients’ lives drive us to set new benchmarks in the industry.
Reliability
We are committed to creating a working environment where employees can trust each other while delivering high-quality products and services that healthcare professionals as well as patients can rely on.
Our Mission
ZuriMED strives to develop innovative technologies that overcome current limitations in soft tissue repair by leveraging our pragmatic, agile, and motivated team in close collaboration with healthcare professionals.
Our Vision
We envision a future where our products have redefined modern surgical practices to maximize the quality of physicians’ treatment options and patients’ lives.

ZuriMED originated in Zurich, Switzerland, and is part of the Swiss health cluster. Surrounded by world-leading universities and orthopedic healthcare institutes, we have unique access to high-quality labs, clinical knowledge, and exceptionally skilled talents.

The startup spun off from the University of Zurich and ETH Zurich and is supported by Balgrist Beteiligungs AG, currently located at Balgrist Campus. With this, we benefit from close collaborations with research groups and clinicians, accelerating the transition from bench to bedside.
Our Values
Innovation
We embrace creativity and entrepreneurial thinking, developing groundbreaking technologies to pioneer advancements and reshape the future of healthcare.
Ambition
Our relentless pursuit of excellence and our vision of improving patients’ lives drive us to set new benchmarks in the industry.
Reliability
We are committed to creating a working environment where employees can trust each other while delivering high-quality products and services that healthcare professionals as well as patients can rely on.
Our Mission
ZuriMED strives to develop innovative technologies that overcome current limitations in soft tissue repair by leveraging our pragmatic, agile, and motivated team in close collaboration with healthcare professionals.
Our Vision
We envision a future where our products have redefined modern surgical practices to maximize the quality of physicians’ treatment options and patients’ lives.
Our Impact
At ZuriMED, we are driven by the mission of sustainable innovation and guided by our vision for a better future — not only revolutionizing soft tissue repair in sports medicine but also fostering healthy competition in the MedTech industry while focusing on local environmental impact.
At ZuriMED, we are driven by the mission of sustainable innovation and guided by our vision for a better future — not only revolutionizing soft tissue repair in sports medicine but also fostering healthy competition in the MedTech industry while focusing on local environmental impact.
Our Goal
Creating a fair workspace where diversity and inclusion are embraced, while focusing on local initiatives and partnerships. We not only take the well-being of our patients and employees seriously but also uphold our responsibility to local communities.
Our Goal
Creating a fair workspace where diversity and inclusion are embraced, while focusing on local initiatives and partnerships. We not only take the well-being of our patients and employees seriously but also uphold our responsibility to local communities.
Our Commitment
As part of our commitment to a healthier future, we’ve incorporated the United Nations Sustainable Development Goals (SDGs) into our ESG strategy. The ESG (Environmental, Social, and Governance) strategy is a framework that integrates sustainability, ethical practices, and responsible governance into our company’s operations, decision-making, and long-term goals to drive positive environmental and social impact while creating value for stakeholders. The SDG goals serve as a global blueprint to address pressing challenges—such as climate change, health, and social equity—and we’re proud to do our part. By aligning our business practices with specific SDGs, we aim to minimize our environmental footprint, ensure ethical operations, and make a positive impact on the communities we serve. We believe that by working towards these shared goals, we can contribute to a healthier, more sustainable world for future generations.
Our Commitment
As part of our commitment to a healthier future, we’ve incorporated the United Nations Sustainable Development Goals (SDGs) into our ESG strategy. The ESG (Environmental, Social, and Governance) strategy is a framework that integrates sustainability, ethical practices, and responsible governance into our company’s operations, decision-making, and long-term goals to drive positive environmental and social impact while creating value for stakeholders. The SDG goals serve as a global blueprint to address pressing challenges—such as climate change, health, and social equity—and we’re proud to do our part. By aligning our business practices with specific SDGs, we aim to minimize our environmental footprint, ensure ethical operations, and make a positive impact on the communities we serve. We believe that by working towards these shared goals, we can contribute to a healthier, more sustainable world for future generations.
Environmental (E)
Goal 12
Taking responsibility with a green office building policy, including recycling and the sustainable use of energy.
Goal 4
Educating employees on sustainable practices both in the office and at home.
Social (S)
Goal 9
Driving innovation in the MedTech industry.
Goal 11
Supporting local communities and initiatives like Tischlein Deck Dich through volunteering activities.
Governance (G)
Goal 17
Partnering with universities to leverage expertise for innovative health solutions.
Our Team
Our driven and dynamic team comprises highly skilled professionals with diverse expertise, drawing on experience from top research institutes and trailblazing companies.

Xiang Li

Elias Bachmann

Pol Banzet

Sascha Brun

Andrea Möhl

Sebastian Arevalo

Ronja Senn

Catherine Trojer Marcelo

Mariano Perez Chaher

Ricardo Ribeiro

Esteban Doig Cramer

Carlota Sole Escobar

Esteban Ongini

Janick Eglauf

Dominic Spothelfer

Cornelius Schlegel

Simon Schnydrig

Blorenta Murseli

Luana Hess

Cherilyn Camichel

Alicia Wirz

Maria Doikova

Till Häussner

Giuditta Thoma
Our Board of Directors
Our Board of Directors is comprised of world-leading scientists, consultants and clinicians supporting the company in their field of expertise.
Prof. Dr. Jess Snedeker
President of the Board of Directors
Ulrich Looser
Member of the Board of Directors
Dr. med. Dominique Tschudi
Vice-President of the Board of Directors
Dr. Helen (Ying) Yang
Member of the Board of Directors
Dr. Xiang Li
Member of the Board of Directors
Prof. Dr. Robert Frigg
Member of the Board of Directors
Chan-Yuan Lu
Member of the Board of Directors
Our driven and dynamic team comprises highly skilled professionals with diverse expertise, drawing on experience from top research institutes and trailblazing companies.

Xiang Li

Elias Bachmann

Pol Banzet

Sascha Brun

Andrea Möhl

Sebastian Arevalo

Ronja Senn

Catherine Trojer Marcelo

Mariano Perez Chaher

Ricardo Ribeiro

Esteban Doig Cramer

Carlota Sole Escobar

Esteban Ongini

Janick Eglauf

Dominic Spothelfer

Cornelius Schlegel

Simon Schnydrig

Blorenta Murseli

Luana Hess

Cherilyn Camichel

Alicia Wirz

Maria Doikova

Till Häussner

Giuditta Thoma
Our Board of Directors
Our Board of Directors is comprised of world-leading scientists, consultants and clinicians supporting the company in their field of expertise.
Prof. Dr. Jess Snedeker
President of the Board of Directors
Ulrich Looser
Member of the Board of Directors
Dr. med. Dominique Tschudi
Vice-President of the Board of Directors
Dr. Helen (Ying) Yang
Member of the Board of Directors
Dr. Xiang Li
Member of the Board of Directors
Prof. Dr. Robert Frigg
Member of the Board of Directors
Chan-Yuan Lu
Member of the Board of Directors
History
Scroll through our company’s history and explore the key milestones that have shaped ZuriMED’s journey.
Scroll through our company’s history and explore the key milestones that have shaped ZuriMED’s journey.
2024 | FiberLocker System receives FDA Clearance
In December 2024, ZuriMED Technologies AG celebrated a significant achievement: the FDA clearance of our 510(k) submission for the FiberLocker® System. This represents the first clinical indication of the pioneering Surgical-Fiberlock® technology. We anticipate a limited U.S. market release of the SpeedPatch® PET and FiberLocker® Instrument SN in early 2025, allowing patients to soon benefit from this new technology.
2023 | ZuriMED closes Series-A financing round & receives Innosuisse Swiss Accelerator Grant
The financing round was led by Chindex Medical Limited (Hong Kong), followed by Yellowstone Holding AG (Geneva) and a group of private investors that includes leading orthopaedic surgeons from Switzerland, Germany, France, and the United States. An additional non-diluting funding from Innosuisse will greatly expedite the development and regulatory registration process of a second clinical indication.
2022 | ZuriMED obtains Innosuisse Scale-up Award & Innosuisse Project Grant
Thanks to this award, ZuriMED can access the second phase of the Scale-up Coaching program to further accelerate the growth in Switzerland and the expansion into new global markets. The Project Grant supports the co-development with research partner University Hospital Balgrist on ZuriMED’s breakthrough technology for soft tissue repair.
2021 | ISO 13485 certificate obtained
ZuriMED achieves ISO 13485 certification through BSI
2020 | ZuriMED closes a license deal with an international medical device company
One of ZuriMED’s endocortical fixation technologies for soft tissue repair has been licensed to an international medical device company. A strategic partnership has been established to work together to bring this technology to clinical applications.
2019 | ZuriMED obtains the Innosuisse Certificate
The company has now obtained the Innosuisse certificate in recognition for the potential of its technology and solutions. The role of Innosuisse – the Swiss Innovation Agency – is to promote science-based innovation in the interests of industry and society in Switzerland.
2018 | Capital increase – loan conversion executed
Loan conversion of the seed round investment into equity.
2017 | Start of Innosuisse funded First-in-man study
Clinical trial on ZuriMED’s first product, the BTB-Converter™ was approved by Swissethics and sponsored by Innosuisse (formerly Commission for Technology and Innovation in Switzerland [CTI]).
2016 | Seed round investment received
Investment in terms of convertible loan. ZuriMED moves into the newly opened Balgrist Campus.
2015 | Incorporation of ZuriMED Technologies AG
Winner of Venture Kick Final, Switzerland’s largest start-up acceleration program. Presenting 2nd best business plan by >>venture>>, the leading competition for entrepreneurs in Switzerland, a joint initiative of ETH Zurich, McKinsey & Company, Knecht Holding, Innosuisse and EPFL.
2024 | FiberLocker System receives FDA Clearance
In December 2024, ZuriMED Technologies AG celebrated a significant achievement: the FDA clearance of our 510(k) submission for the FiberLocker® System. This represents the first clinical indication of the pioneering Surgical-Fiberlock® technology. We anticipate a limited U.S. market release of the SpeedPatch® PET and FiberLocker® Instrument SN in early 2025, allowing patients to soon benefit from this new technology.
2023 | ZuriMED closes Series-A financing round & receives Innosuisse Swiss Accelerator Grant
The financing round was led by Chindex Medical Limited (Hong Kong), followed by Yellowstone Holding AG (Geneva) and a group of private investors that includes leading orthopaedic surgeons from Switzerland, Germany, France, and the United States. An additional non-diluting funding from Innosuisse will greatly expedite the development and regulatory registration process of a second clinical indication.
2022 | ZuriMED obtains Innosuisse Scale-up Award & Innosuisse Project Grant
Thanks to this award, ZuriMED can access the second phase of the Scale-up Coaching program to further accelerate the growth in Switzerland and the expansion into new global markets. The Project Grant supports the co-development with research partner University Hospital Balgrist on ZuriMED’s breakthrough technology for soft tissue repair.
2021 | ISO 13485 certificate obtained
ZuriMED achieves ISO 13485 certification through BSI
2020 | ZuriMED closes a license deal with an international medical device company
One of ZuriMED’s endocortical fixation technologies for soft tissue repair has been licensed to an international medical device company. A strategic partnership has been established to work together to bring this technology to clinical applications.
2019 | ZuriMED obtains the Innosuisse Certificate
The company has now obtained the Innosuisse certificate in recognition for the potential of its technology and solutions. The role of Innosuisse – the Swiss Innovation Agency – is to promote science-based innovation in the interests of industry and society in Switzerland.
2018 | Capital increase – loan conversion executed
Loan conversion of the seed round investment into equity.
2017 | Start of Innosuisse funded First-in-man study
Clinical trial on ZuriMED’s first product, the BTB-Converter™ was approved by Swissethics and sponsored by Innosuisse (formerly Commission for Technology and Innovation in Switzerland [CTI]).
2016 | Seed round investment received
Investment in terms of convertible loan. ZuriMED moves into the newly opened Balgrist Campus.
2015 | Incorporation of ZuriMED Technologies AG
Winner of Venture Kick Final, Switzerland’s largest start-up acceleration program. Presenting 2nd best business plan by >>venture>>, the leading competition for entrepreneurs in Switzerland, a joint initiative of ETH Zurich, McKinsey & Company, Knecht Holding, Innosuisse and EPFL.
Careers
We are constantly seeking innovative talents. If you believe you are the perfect fit for our team, please send a spontaneous application to: application@zurimed.com
We are looking forward to meeting you!